MedTrace Logo

FCI-Glioblastoma Study

NCT07443176 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2026-04-30

No results posted yet for this study

Summary

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can tell the difference between tumour growth (progression) and 'pseudo-progression' (which looks like tumour but is not cancerous tissue) in patients with glioblastoma. The main question it aims to answer is:

• Can FCI differentiate glioblastoma progression from pseudo-progression?

Participants will undergo a standard MRI scan and an FCI scan, three times during the study. One before starting adjuvant chemotherapy, another one after three cycles and one at the end of treatment.

Conditions

  • Glioblastom WHO Grade 4

Interventions

OTHER

Baseline Field-Cycling Imaging research scan

FCI scan at baseline

OTHER

Baseline 3T MRI research scan

MRI scan at baseline

OTHER

Second Field-Cycling Imaging research scan

FCI scan after three cycles of chemotherapy

OTHER

Second 3T MRI research scan

MRI scan after three cycles of chemotherapy

OTHER

Final Field-Cycling Imaging research scan

FCI scan at the end of chemotherapy

OTHER

Final 3T MRI research scan

MRI scan at the end of chemotherapy

Sponsors & Collaborators

  • NHS Grampian

    collaborator OTHER_GOV

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Anne Kiltie, Prof · University of Aberdeen

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07443176 on ClinicalTrials.gov